Navigation Links
New Interim Data About Combination Oral Contraceptives
Date:3/25/2011

WAYNE, N.J., March 25, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

Specifically, the new data provides healthcare providers with information regarding when the VTE risk associated with COCs is highest.  The risk of VTE is highest during the first year of COC use and the new data suggest that this increased risk is greatest during the first six months.  This risk is greatest when first starting the Pill and when restarting the same or a different Pill after a four week or greater break.  

The new data are from the ongoing, Long-Term Active Surveillance Study for Oral Contraceptives (LASS) – a large, multinational, prospective cohort, five-year follow-up safety study to the European Active Surveillance (EURAS) study. Cardiovascular events, including VTE, were the main clinical outcomes studied in LASS.   Together, these two studies will provide data for up to ten years on women using various COCs.  

"As a leader in women's contraception, we believe it is important for Bayer to take the lead in studying and communicating the risks and benefits of COCs," said Leo Plouffe, MD, Vice President, US Medical Affairs, Women's Healthcare, Bayer HealthCare Pharmaceuticals.  "The new information is helpful because while healthcare providers have long known about the risk of VTE associated with COCs, there was little information to indicate that there was an increased risk in women restarting COCs after a four week or greater period of non-use.  This new information should provide both healthcare providers and women who choose a COC for contraception with additional information when making the deci
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
(Date:7/22/2014)... July 22, 2014 Getting breast implants is ... completely optional or due to medical necessity. Either way, women ... to prepare for it, says Robert Kraft, MD, Plastic Surgeon ... implant removal surgeries are performed each year in the United ... 70 percent of those procedures stem from three main problems: ...
(Date:7/22/2014)... Southlake, TX (PRWEB) July 22, 2014 ... proving to address skin laxity with results that are ... opposed to topically treating the skin with radio frequency, ... probes which are inserted under the skin to “inject” ... studies have shown that this single treatment solution for ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 PowerObjects, ... service, support, education, and add-ons for Microsoft Dynamics ... Inner Circle, an elite group of the most ... with sales achievements that rank them in the ... of partners. Members of the Microsoft Dynamics Inner ...
(Date:7/21/2014)... human nature to hate losing. , Unfortunately, it,s ... abandoning a solid strategy and thus increasing your chances ... conclusion of a Brigham Young University study published this ... finding is based on an analysis of two decades ... focused on whether coaches adjusted their personnel following games ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... HealthDay Reporter , TUESDAY, May 17 (HealthDay News) ... birth defects in women taking these drugs during the first ... the drugs are relatively new, further studies are needed to ... In a large study of children born in Denmark, ...
... City, the prevalence of asthma among children entering school ... children growing up within walking distance of each other ... asthma. In the first comprehensive effort to understand ... Mailman School of Public Health compared the household presence ...
... . , Pediatric and young adult leukemia and ... the Cole Foundation,s announcement that it would provide more than ... four McGill University young scientists. "The Cole Foundation is dedicated ... the age of 25, and the research projects we finance ...
... from Boston University School of Medicine (BUSM) have discovered ... syndromes. The team connected pharmacological properties of the Novartis ... for the first time after investigating adverse reactions suffered ... treatment of osteoporosis. These findings appear online in the ...
... -- A gene variation that causes faulty cholesterol regulation also ... may be a reason why some women can,t get pregnant, ... more than 200 infertile women who were undergoing in vitro ... the scavenger receptor class B type 1 (SCARB1) gene. ...
... the intermittent interruption of breathing that occurs in patients with ... cells and increased tumor growth in mice, according to researchers ... mouse models tended to contain more dead cells, indicating a ... the study will be presented at the ATS 2011 International ...
Cached Medicine News:Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 2Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 3Health News:Cockroach allergens in homes associated with prevalence of childhood asthma in some neighborhoods 2Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Obstructive sleep apnea linked to cancer growth in mice 2Health News:Obstructive sleep apnea linked to cancer growth in mice 3
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: